Internet Archive Scholar

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities [article]

Maryam Yousefi, Gábor Boross, Carly Weiss, Christopher W. Murray, Jess D. Hebert, Hongchen Cai, Emily L. Ashkin, Saswati Karmakar, Laura Andrejka, Leo Chen, Minwei Wang, Min K. Tsai (+10 others)
2021 bioRxiv   pre-print

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (18.3 MB)
https://web.archive.org/web/20220119073822/https://www.biorxiv.org/content/biorxiv/early/2021/10/21/2021.10.20.464849.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL. The file type is application/pdf.

ABSTRACTLung cancer is the leading cause of cancer death worldwide, with lung adenocarcinoma being the most common subtype. Many oncogenes and tumor suppressor genes are altered in this cancer type and the discovery of oncogene mutations has led to the development of targeted therapies and better clinical outcomes. However, a large fraction of lung adenocarcinomas lacks mutations in known oncogenes, and the genesis and treatment of these oncogene-negative tumors remain enigmatic. Here, we
more » ... m iterative in vivo functional screens with quantitative autochthonous mouse model systems to uncover the genetic and biochemical changes that enable efficient lung tumor initiation in the absence of oncogene alterations. Through the generation of hundreds of diverse combinations of tumor suppressor alterations, we demonstrate that inactivation of suppressors of the RAS and PI3K pathways drive the development of oncogene- negative lung adenocarcinoma. Pathway-level human genomic data analysis and histology identified RAS/MAPK and PI3K pathway activation as a common event in oncogene-negative human lung adenocarcinomas. We demonstrate that oncogene-negative tumors and cell lines with activated RAS/MAPK and PI3K pathways are vulnerable to pharmacological inhibition of these signaling axes. Collectively, these results transform our understanding of this prevalent yet understudied subtype of lung adenocarcinoma.STATEMENT OF SIGNIFICANCEMany lung adenocarcinomas do not have mutations in known proto-oncogenes, and as a result, targeted therapies are unavailable for treating these patients. Here, we uncover driver pathways in a subset of these oncogene-negative lung adenocarcinomas and demonstrate the therapeutic value of inhibiting these pathways.
doi:10.1101/2021.10.20.464849 fatcat:tv6wzqo4sje65k4ffguew5p3b4
Citation

Maryam Yousefi, Gábor Boross, Carly Weiss, Christopher W. Murray, Jess D. Hebert, Hongchen Cai, Emily L. Ashkin, Saswati Karmakar, Laura Andrejka, Leo Chen, Minwei Wang, Min K. Tsai, Wen-Yang Lin, Chuan Li, Pegah Yakhchalian, Caterina I. Colón, Su-Kit Chew, Pauline Chu, Charles Swanton, Christian A. Kunder, Dmitri A. Petrov, Monte M. Winslow. "Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities." bioRxiv (2021)